Pharmabiz

BlueRock announces first Parkinson’s disease patient treated in pivotal phase III trial of investigational cell therapy bemdaneprocel

Cambridge, Massachusetts Tuesday, September 23, 2025, 18:00 Hrs [IST] ...
Pharmabiz

NIMHANS launches AYUSH-MANN to create awareness on integrative approaches to treat mental-neuro disorders

NIMHANS launches AYUSH-MANN to create awareness on integrative approaches to treat mental-neuro disorders: Our Bureau, Bengaluru Tuesday, September 23, 2025, 17:15 Hrs [IST] Natio ...
Pharmabiz

AstraZeneca announces EMA committee recommends approval of Koselugo to treat plexiform neurofibromas in adults with neurofibromatosis type 1

AstraZeneca announces EMA committee recommends approval of Koselugo to treat plexiform neurofibromas in adults with neurofibromatosis type 1: Cambridge, UK Tuesday, September 23, ...
Pharmabiz

US FDA extends target action date to review Sanofi’s NDA for tolebrutinib in non-relapsing, secondary progressive multiple sclerosis

US FDA extends target action date to review Sanofi’s NDA for tolebrutinib in non-relapsing, secondary progressive multiple sclerosis: Paris Tuesday, September 23, 2025, 16:00 Hr ...
Pharmabiz

FDI in hospitals and diagnostics hits USD 1.56 billion in FY2025, up 2.3x since FY2022: Rubix Data Sciences

FDI in hospitals and diagnostics hits USD 1.56 billion in FY2025, up 2.3x since FY2022: Rubix Data Sciences: Our Bureau, Mumbai Tuesday, September 23, 2025, 15:50 Hrs [IST] Indias ...
Pharmabiz

Apollo AyurVAID Hospitals on national Ayurveda Day reinstates focus on safety, quality and measurable clinical outcomes

Apollo AyurVAID Hospitals on national Ayurveda Day reinstates focus on safety, quality and measurable clinical outcomes: Our Bureau, Bengaluru Tuesday, September 23, 2025, 15:40 H ...
Pharmabiz

Laxmi Dental partners with lending platform Fibe to facilitate finance for dental procedures

Laxmi Dental partners with lending platform Fibe to facilitate finance for dental procedures: Our Bureau, New Delhi Tuesday, September 23, 2025, 15:30 Hrs [IST] Mumbai-based Laxmi ...
Pharmabiz

Roche announces positive results from phase III evERA study of giredestrant in combo with everolimus in ER-positive advanced breast cancer

Roche announces positive results from phase III evERA study of giredestrant in combo with everolimus in ER-positive advanced breast cancer: Basel Tuesday, September 23, 2025, 15:0 ...
Pharmabiz

Agilus Diagnostics in cancer genomics introduces comprehensive genomic profiling of 500+genes

Agilus Diagnostics in cancer genomics introduces comprehensive genomic profiling of 500+genes: Our Bureau, Bengaluru Tuesday, September 23, 2025, 14:45 Hrs [IST] Agilus Diagnostic ...
Pharmabiz

Vidal Health and Serum Institute of India collaborate on HPV vaccine access

Vidal Health and Serum Institute of India collaborate on HPV vaccine access: Our Bureau, Mumbai Tuesday, September 23, 2025, 14:30 Hrs [IST] In a step towards preventive and digit ...
Pharmabiz

Centrient Pharma expands global CSR efforts to boost healthcare, elderly support, and sustainability

Centrient Pharma expands global CSR efforts to boost healthcare, elderly support, and sustainability: Our Bureau, Bengaluru Tuesday, September 23, 2025, 14:15 Hrs [IST] Centrient ...
Pharmabiz

EMA committee recommends approval of Tezspire for chronic rhinosinusitis with nasal polyps

AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).